SPIE SA : Is the distribution phase coming to an end ?
Entry price | Target | Stop-loss | Potential |
---|
€26.56 |
€28.7 |
€25.9 |
+8.06% |
---|
SPIE SA shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
● The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths● With regards to fundamentals, the enterprise value to sales ratio is at 0.64 for the current period. Therefore, the company is undervalued.
● The company has a low valuation given the cash flows generated by its activity.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses● The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
● The company sustains low margins.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.